Company: CI
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001739940-25-000028
Chunk: 63

Company: Cigna Group
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 63
---
 liabilities1,702 (125)Pharmacy and other service costs payable995 7,820 Accounts payable and Accrued expenses and other liabilities(1,020)(15)Other, net417 225 NET CASH PROVIDED BY OPERATING ACTIVITIES34 5,105 Cash Flows from Investing ActivitiesProceeds from investments sold:Debt securities and equity securities272 393 Investment maturities and repayments:Debt securities and equity securities553 414 Commercial mortgage loans90 37 Other sales, maturities and repayments (primarily short-term and other long-term investments)431 451 Investments purchased or originated:Debt securities and equity securities(1,512)(493)Commercial mortgage loans(62)(52)Other (primarily short-term and other long-term investments)(761)(865)Property and equipment purchases, net(612)(670)Divestitures, net of cash sold2,346 — Renewable energy tax credit equity investments(327)(335)Other, net(18)(15)NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES400 (1,135)Cash Flows from Financing ActivitiesDeposits and interest credited to contractholder deposit funds74 84 Withdrawals and benefit payments from contractholder deposit funds(137)(135)Net change in short-term debt296 (467)Repayment of long-term debt(1,600)(3,000)Net proceeds on issuance of long-term debt— 4,462 Repurchase of common stock(2,620)(5,012)Issuance of common stock141 221 Common stock dividend paid(813)(793)Other, net(355)(198)NET CASH USED IN FINANCING ACTIVITIES(5,014)(4,838)Effect of foreign currency rate changes on cash, cash equivalents and restricted cash 35 (12)Net decrease in cash, cash equivalents and restricted cash(4,545)(880)Cash, cash equivalents and restricted cash January 1, (1)8,931 8,337 Cash, cash equivalents and restricted cash June 30, (1)4,386 7,457 Cash and cash equivalents reclassified to assets of businesses held for sale— (625)Cash, cash equivalents and restricted cash June 30, per Consolidated Balance Sheets (1)$4,386 $6,832 Supplemental Disclosure